Literature DB >> 33775089

Titrating Polyarginine into Nanofibers Enhances Cyclic-Dinucleotide Adjuvanticity in Vitro and after Sublingual Immunization.

Sean H Kelly1, Benjamin J Cossette1, Ajay K Varadhan1, Yaoying Wu1, Joel H Collier1.   

Abstract

Effective sublingual peptide immunization requires overcoming challenges of both delivery and immunogenicity. Mucosal adjuvants, such as cyclic-dinucleotides (CDN), can promote sublingual immune responses but must be codelivered with the antigen to the epithelium for maximum effect. We designed peptide-polymer nanofibers (PEG-Q11) displaying nona-arginine (R9) at a high density to promote complexation with CDNs via bidentate hydrogen-bonding with arginine side chains. We coassembled PEG-Q11 and PEG-Q11R9 peptides to titrate the concentration of R9 within nanofibers. In vitro, PEG-Q11R9 fibers and cyclic-di-GMP or cyclic-di-AMP adjuvants had a synergistic effect on enhancing dendritic cell activation that was STING-dependent and increased monotonically with increasing R9 concentration. The polyvalent display of R9 on assembled nanofibers was significantly more effective at promoting CDN-mediated DC activation in vitro than mixing nanofibers with an equimolar concentration of unassembled R9 peptide. The sublingual administration of nanofibers revealed a bell-shaped trend between increasing R9 concentration and enhancements to antigen trafficking and the activation of DCs in the draining lymph nodes. Intermediate levels of R9 within sublingually administered PEG-Q11 fibers were optimal for immunization, suggesting a balance between polyarginine's ability to sequester CDNs along the nanofiber and its potentially detrimental mucoadhesive interactions. These findings present a potentially generalizable biomaterial strategy for enhancing the potency of CDN adjuvants and reveal important design considerations for the nascent field of sublingual biomaterial immunization.

Entities:  

Keywords:  STING; adjuvant; biomaterials; polyarginine; sublingual; vaccine

Mesh:

Substances:

Year:  2021        PMID: 33775089      PMCID: PMC8822437          DOI: 10.1021/acsbiomaterials.0c01429

Source DB:  PubMed          Journal:  ACS Biomater Sci Eng        ISSN: 2373-9878


  57 in total

1.  Polyarginine enters cells more efficiently than other polycationic homopolymers.

Authors:  D J Mitchell; D T Kim; L Steinman; C G Fathman; J B Rothbard
Journal:  J Pept Res       Date:  2000-11

2.  Controlled and targeted release of antigens by intelligent shell for improving applicability of oral vaccines.

Authors:  Lei Zhang; Zhanzhuang Zeng; Chaohua Hu; Susan L Bellis; Wendi Yang; Yintao Su; Xinyan Zhang; Yunkun Wu
Journal:  Biomaterials       Date:  2015-11-14       Impact factor: 12.479

3.  Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen.

Authors:  A W Olsen; P R Hansen; A Holm; P Andersen
Journal:  Eur J Immunol       Date:  2000-06       Impact factor: 5.532

4.  Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells.

Authors:  Chih-Hang Anthony Tang; Joseph A Zundell; Sujeewa Ranatunga; Cindy Lin; Yulia Nefedova; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  Cancer Res       Date:  2016-03-07       Impact factor: 12.701

5.  PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination.

Authors:  Hardeep S Oberoi; Yvonne M Yorgensen; Audrey Morasse; Jay T Evans; David J Burkhart
Journal:  J Control Release       Date:  2015-11-06       Impact factor: 9.776

6.  Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses.

Authors:  James J Moon; Heikyung Suh; Anna Bershteyn; Matthias T Stephan; Haipeng Liu; Bonnie Huang; Mashaal Sohail; Samantha Luo; Soong Ho Um; Htet Khant; Jessica T Goodwin; Jenelyn Ramos; Wah Chiu; Darrell J Irvine
Journal:  Nat Mater       Date:  2011-02-20       Impact factor: 43.841

7.  Designer vaccine nanodiscs for personalized cancer immunotherapy.

Authors:  Rui Kuai; Lukasz J Ochyl; Keith S Bahjat; Anna Schwendeman; James J Moon
Journal:  Nat Mater       Date:  2016-12-26       Impact factor: 43.841

8.  Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses.

Authors:  Youhui Si; Yi Wen; Sean H Kelly; Anita S Chong; Joel H Collier
Journal:  J Control Release       Date:  2018-04-17       Impact factor: 9.776

9.  Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.

Authors:  Geoffrey M Lynn; Christine Sedlik; Faezzah Baharom; Yaling Zhu; Ramiro A Ramirez-Valdez; Vincent L Coble; Kennedy Tobin; Sarah R Nichols; Yaakov Itzkowitz; Neeha Zaidi; Joshua M Gammon; Nicolas J Blobel; Jordan Denizeau; Philippe de la Rochere; Brian J Francica; Brennan Decker; Mateusz Maciejewski; Justin Cheung; Hidehiro Yamane; Margery G Smelkinson; Joseph R Francica; Richard Laga; Joshua D Bernstock; Leonard W Seymour; Charles G Drake; Christopher M Jewell; Olivier Lantz; Eliane Piaggio; Andrew S Ishizuka; Robert A Seder
Journal:  Nat Biotechnol       Date:  2020-01-13       Impact factor: 68.164

10.  Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis.

Authors:  Lucas S Shores; Sean H Kelly; Kelly M Hainline; Jutamas Suwanpradid; Amanda S MacLeod; Joel H Collier
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

View more
  2 in total

Review 1.  Nanofiber Carriers of Therapeutic Load: Current Trends.

Authors:  Ivana Jarak; Inês Silva; Cátia Domingues; Ana Isabel Santos; Francisco Veiga; Ana Figueiras
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

Review 2.  Immunostimulatory Polymers as Adjuvants, Immunotherapies, and Delivery Systems.

Authors:  Adam M Weiss; Samir Hossainy; Stuart J Rowan; Jeffrey A Hubbell; Aaron P Esser-Kahn
Journal:  Macromolecules       Date:  2022-08-04       Impact factor: 6.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.